Food and Drug Administration Approval Summary: Odevixibat (Bylvay) for the Treatment of Pruritus With Progressive Familial Intrahepatic Cholestasis
SoJeong Yi(United States Food and Drug Administration), Ruby Mehta(Center for Drug Evaluation and Research), Lili Garrard(University of Kansas Medical Center), Marian M. Strazzeri(Office of Science), Toru Matsubayashi(Johns Hopkins University), Rebecca Hager(Office of Science), In‐Sook Kim(Frederick National Laboratory for Cancer Research)
Cited by 6
Related Papers
Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine
|Journal of Lipid Research|2007|595
Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice
|Carcinogenesis|2006|359
DYRK1A-mediated Hyperphosphorylation of Tau
|Journal of Biological Chemistry|2007|273
Pregnane X receptor activation ameliorates DSS-induced inflammatory bowel disease via inhibition of NF-κB target gene expression
|American Journal of Physiology-Gastrointestinal and Liver Physiology|2006|230
Hepatocyte nuclear factor 4α in the intestinal epithelial cells protects against inflammatory bowel disease
|Inflammatory Bowel Diseases|2008|163